News - Velcade

Filter

Current filters:

Velcade

Popular Filters

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

10-06-2014

Certain targeted therapies enjoy extensive but incomplete coverage in Brazil and Mexico through complex…

BiosimilarsBrazilJohnson & JohnsonMabTheraMexicoOncologyPharmaceuticalPricingRocheVelcade

ASCO 2014: Takeda, Roche and Celgene present results

ASCO 2014: Takeda, Roche and Celgene present results

02-06-2014

A host of results have been presented by global pharma majors at the 2014 Annual Meeting of the American…

AbraxaneCelgeneOncologyPharmaceuticalResearchRocheTakeda PharmaceuticalsUSAVelcade

UK NICE backs Janssen’s Velcade for multiple myeloma

UK NICE backs Janssen’s Velcade for multiple myeloma

21-03-2014

In new draft guidance published today, UK drugs watchdog the National Institute for Health and Care Excellence…

JanssenJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

NICE seeks more data on J&J’s Velcade for multiple myeloma

NICE seeks more data on J&J’s Velcade for multiple myeloma

12-11-2013

In draft guidance published today, the UK’s drugs watchdog the National Institute of Health and Care…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalPricingRegulationVelcade

EU backs wider use of Velcade

09-08-2013

The European Commission has approved the use of Johnson & Johnson (NYSE: JNJ) European subsidiary Janssen-Cilag's…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationVelcade

Strong results from meta-analysis of Takeda's Velcade in multiple myeloma

08-04-2013

Millennium, the USA-based oncology unit of Japan's largest drugmaker Takeda Pharmaceutical (TSE:4502),…

Millennium PharmaceuticalsOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

New molecule to target pancreatic cancer treatment found by Mayo Clinic researchers

06-01-2013

A new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more…

bortezomibJohnson & JohnsonOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

First-line multiple myeloma patient share in Europe is variable by country

29-08-2012

Despite the considerable heterogeneity across different European countries, surveyed hematologist-oncologists…

AlkeranBiotechnologyCelgeneGlaxoSmithKlineHealthcareJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalThalomidVelcade

Johnson & Johnson pulls EU submission for Velcade use in NHL

05-07-2012

The European Medicines Agency has been formally notified by US health care giant Johnson & Johnson's…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationVelcade

5.6% annual growth forecast for multiple myeloma drug market to 2020

21-12-2011

Driven by further penetration of Celgene’s Revlimid (lenalidomide) into the first-line setting and…

CelgeneGlobalJanssen-CilagMarkets & MarketingOncologyPharmaceuticalRevlimidTakeda PharmaceuticalsVelcade

Back to top